AMENDMENT TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • November 1st, 2006 • Minrad International, Inc. • Pharmaceutical preparations
INTERNATIONAL CAPITAL ADVISORY INC. (“ICA”) and MINRAD INC. (“Minrad”) hereby enter into this Amendment to Advisory Consulting Agreement (the “Amendment”) and agree as follows:
AMENDED AND RESTATED ADVISORY CONSULTING AGREEMENT Dated as of July 13, 2007Advisory Consulting Agreement • October 11th, 2007 • Southridge Technology Group, Inc. • Services-computer programming services
This Amended and Restated Advisory Consulting Agreement (this “Agreement”) amends and restates the prior Advisory Consulting Agreement, dated as of September 18, 2006, by and between in its entirety RxElite (“RxElite” or the “Company”) and International Capital Advisory Inc. (“ICA”).
ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • January 7th, 2019 • Cure Pharmaceutical Holding Corp. • Plastics, foil & coated paper bags • California
This Advisory Board Consulting Agreement (the “Agreement”) is made and effective as of December 14, 2018 (the “Effective Date”), by and between CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”) and Michael J. Willner, an individual (the “Consultant” and together with the Company, the “Parties”).
EXHIBIT 10.129 September 13, 2006 PRIVATE & CONFIDENTIAL VIA E-MAIL Mr. Timothy J. Mclntyre President & CEO VYTERIS HOLDINGS (NEVADA), INC. 13-01 Pollitt Drive Fair Lawn, NJ 07410 Dear Tim: ADVISORY CONSULTING AGREEMENT Pursuant to our discussions,...Advisory Consulting Agreement • November 13th, 2006 • Vyteris Holdings (Nevada), Inc. • Pharmaceutical preparations
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENT (the “Amendment”) dated as of December 21, 2018, by and between KATALYST SECURITIES LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Katalyst”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
ContractAdvisory Consulting Agreement • January 28th, 2022 • ProMIS Neurosciences Inc. • Pharmaceutical preparations • British Columbia
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]
EXHIBIT 10.1 ADVISORY & CONSULTING AGREEMENT This Agreement (the "Agreement") dated as of September 10th, 2001 (the "Effective Date"), by and between SATX, Inc., hereinafter referred to as "SATX" or the "Company" and Terrance Byrne, hereinafter...Advisory & Consulting Agreement • November 20th, 2001 • Satx Inc • Real estate • Georgia
FORM OF ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 17th, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
ADVISORY CONSULTING AGREEMENT (the “Agreement”) dated as of December 12, 2018 (the “Agreement”) by and between [ ], a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (the “CONSULTANT”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENT (the “Amendment”) dated as of December 31, 2018, by and between MAXIM GROUP LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Maxim”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • January 23rd, 2020 • Neurotrope, Inc. • Pharmaceutical preparations • New York
ADVISORY CONSULTING AGREEMENT (the “Agreement”) dated as of January 22, 2020 (the “Agreement”) by and between KATALYST SECURITIES LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Katalyst”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
